Overview

Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Evaluation if physostigmine reduces symptoms in patients who has developed a delirium in Intensive care after a surgery
Phase:
Phase 3
Details
Lead Sponsor:
PD Dr. Bertram Scheller
Collaborators:
Dr. Franz Köhler Chemie GmbH (study medication and labeling)
University Hospital, Frankfurt
Treatments:
Pharmaceutical Solutions
Physostigmine